Karyopharm Therapeutics Inc (NASDAQ:KPTI) insider Sharon Shacham sold 12,500 shares of the business’s stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $11.65, for a total value of $145,625.00. Following the transaction, the insider now directly owns 726,010 shares of the company’s stock, valued at approximately $8,458,016.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Sharon Shacham also recently made the following trade(s):

  • On Thursday, October 18th, Sharon Shacham sold 10,000 shares of Karyopharm Therapeutics stock. The shares were sold at an average price of $12.63, for a total value of $126,300.00.
  • On Monday, October 8th, Sharon Shacham sold 12,500 shares of Karyopharm Therapeutics stock. The shares were sold at an average price of $15.75, for a total value of $196,875.00.
  • On Friday, September 7th, Sharon Shacham sold 12,500 shares of Karyopharm Therapeutics stock. The shares were sold at an average price of $19.31, for a total value of $241,375.00.

Shares of Karyopharm Therapeutics stock traded up $0.05 on Friday, hitting $11.60. The stock had a trading volume of 786,589 shares, compared to its average volume of 933,786. Karyopharm Therapeutics Inc has a twelve month low of $9.00 and a twelve month high of $21.71. The company has a market capitalization of $721.92 million, a P/E ratio of -4.13 and a beta of 3.93.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, November 8th. The company reported ($0.79) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.09. The firm had revenue of $0.24 million for the quarter, compared to analyst estimates of $1.21 million. As a group, equities research analysts predict that Karyopharm Therapeutics Inc will post -3.18 EPS for the current fiscal year.

Several research analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, August 29th. Robert W. Baird reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, August 8th. Canaccord Genuity reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Karyopharm Therapeutics in a research note on Tuesday, August 7th. Zacks Investment Research raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $21.00 price objective for the company in a research note on Wednesday, July 25th. Finally, BidaskClub downgraded Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 25th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $22.90.

A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. increased its position in Karyopharm Therapeutics by 5.1% during the 3rd quarter. BlackRock Inc. now owns 4,260,531 shares of the company’s stock valued at $72,556,000 after purchasing an additional 204,897 shares during the period. Bank of New York Mellon Corp increased its position in Karyopharm Therapeutics by 2.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 218,594 shares of the company’s stock valued at $3,723,000 after purchasing an additional 4,576 shares during the period. Candriam Luxembourg S.C.A. increased its position in Karyopharm Therapeutics by 120.6% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 1,085,500 shares of the company’s stock valued at $18,486,000 after purchasing an additional 593,500 shares during the period. Los Angeles Capital Management & Equity Research Inc. increased its position in Karyopharm Therapeutics by 20.9% during the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 40,090 shares of the company’s stock valued at $683,000 after purchasing an additional 6,920 shares during the period. Finally, Wells Fargo & Company MN increased its position in Karyopharm Therapeutics by 14.1% during the 3rd quarter. Wells Fargo & Company MN now owns 42,274 shares of the company’s stock valued at $720,000 after purchasing an additional 5,239 shares during the period. 71.83% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2018/11/10/karyopharm-therapeutics-inc-kpti-insider-sharon-shacham-sells-12500-shares.html.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.

Recommended Story: How can investors find ex-dividend dates?

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.